Published in
American Society for Microbiology, Microbiology Spectrum, 4(10), 2022
DOI: 10.1128/spectrum.02206-22
Links
Tools
Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis
,
Aki Sakurai,
Kazumi Takehana,
Taisuke Enokida,
Koichi Takeda,
Daisuke Ohkushi,
Yohei Doi,
Sohei Harada
Full text: Download
Abstract
Although carbapenems are considered the drug of choice for severe infections caused by extended-spectrum β-lactamase-producing (ESBL)-producing organisms, other therapeutic options are being explored to avoid increasing the selective pressure for carbapenem-resistant organisms. In this study, it was suggested that piperacillin-tazobactam may be as effective as carbapenems for the treatment of mild bacteremia caused by ESBL-producing Escherichia coli in areas where OXA-1 co-production by ESBL-producing E. coli is rare.